Clinical Trial Update: A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

A long-term extension Phase 2 trial update for Janssen's gene therapy JNJ-81201887 (AAVCAGsCD59) in geographic atrophy due to age-related macular degeneration. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• JNJ-81201887 (AAVCAGsCD59) (AAVCAGsCD59)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Geographic Atrophy, Macular Degeneration | Phase 2 | Status: RECRUITING